Skip to content
Review Open access

Pharmacogenomics in Emergency Care: Actionable Genetic Variability, Drug-Related Toxicity, and Precision Prescribing

Sep 2026 · International science journal · 0 citations · 10 references

TL;DR

Pharmacogenomic information showed potential utility for medication selection, dose modification, drug avoidance, risk stratification, and prevention of recurrent adverse events, although its clinical value depends on integration with renal and hepatic function, comorbidities, drug interactions, disease severity, and conventional emergency assessment.

Abstract

Pharmacogenomic variability represents an increasingly relevant determinant of therapeutic response, drug toxicity, and treatment failure in emergency and internal medicine. This study analyzed the clinical applicability of actionable gene–drug interactions associated with acute pharmacological decision-making, severe adverse drug reactions, and the potential integration of genomic information into emergency-care workflows. A structured integrative review based on the Scientific Method was conducted using pharmacogenomic guidelines, implementation studies, regulatory resources, and clinically oriented evidence. Particular attention was given to associations involving CYP2D6, CYP2C19, CYP2C9, VKORC1, G6PD, RYR1, CACNA1S, HLA-B, SLCO1B1, TPMT, and NUDT15. The evidence demonstrated that pharmacogenomic-guided prescribing can be associated with measurable differences in medication safety. In the PREPARE study, clinically relevant adverse drug reactions occurred in 21.0% of patients managed with genotype-guided treatment compared with 27.7% receiving standard care. In an emergency department cohort, actionable pharmacogenomic variants were identified in 99% of patients, while clinically relevant gene–drug pairs were detected in 53%. The analyzed interactions were mainly associated with altered drug metabolism, modified pharmacological sensitivity, severe genetically mediated adverse reactions, and delayed toxicities capable of producing acute-care presentations. Pharmacogenomic information showed potential utility for medication selection, dose modification, drug avoidance, risk stratification, and prevention of recurrent adverse events. Nevertheless, its clinical value depends on integration with renal and hepatic function, comorbidities, drug interactions, disease severity, and conventional emergency assessment. Preemptive testing integrated into electronic health records appears to be one of the most feasible models for emergency implementation because it allows actionable results to be available before time-sensitive treatment decisions. Pharmacogenomics may therefore contribute to a more preventive, individualized, and precise approach to medication safety in acute care, although prospective emergency-specific studies, interoperable systems, population-diverse validation, and equitable access remain necessary for broader implementation.  

Read PDF

Similar papers

Review Open access Aug 2026

Pharmacogenomics of Adverse Drug Reactions: Integrating Genetic Biomarkers into Precision Pharmacotherapy

The integration of pharmacogenomics into routine healthcare has the potential to optimize individualized drug therapy, minimize preventable ADRs, and accelerate the transition toward precision medicine, ultimately improving clinical outcomes and healthcare quality.

Rayapudi Vasavi Sai Saraswati, U. Vattikuti, Arthika Chauhan Laudia et al. · 0 citations
Review Open access Sep 2026

Clinical Pharmacogenomics: Translating Genetic Variation into Individualized Drug Therapy

Clinical pharmacogenomics (PGx) is an emerging component of precision medicine that examines how inherited genetic variation influences an individual's response to medicines. Genetic differences affecting drug-metabolizing enzymes, transporters, receptors, immune pathways and therapeutic targets can contribute to inter...

Kalyani R · 0 citations
Review Open access Aug 2026

Pharmacogenomics in Primary Care: A Narrative Review of DNA-Guided Prescribing in Multimorbidity and Polypharmacy

This narrative review critically examines selected actionable gene–drug pairs, implementation models, conflicting evidence, and unresolved questions for family physicians managing multimorbidity and polypharmacy to propose selective, clinically triggered panel testing as a pragmatic model for primary care.

Luis E. Martínez-Tittonel · 0 citations
Review Open access Aug 2026

Pharmacogenomics-Guided Drug Dose Adjustment in Personalized Medicine: A Systematic Literature Review

Overall, pharmacogenomic-guided dose adjustment is a promising strategy to support safer and more precise pharmacotherapy, although broader implementation requires standardized guidelines, prospective validation, population-specific evidence, and integration into routine healthcare systems.

Zakiah Thahir, Rahmah Mustarin, Rahmadani Rahmadani et al. · 0 citations
Review Open access Aug 2026

Pharmacogenomics in Dentistry: From CYP-Mediated Drug Response to Precision Prescribing in Oral Healthcare.

OBJECTIVE This narrative review critically assesses the clinical relevance of pharmacogenomics within dental genomics, distinguishing clinically actionable applications from emerging or investigational findings. MATERIALS AND METHODS A targeted literature review was conducted in PubMed/MEDLINE, Scopus and Embase for...

Giorgia Pieretto, J. Cusato, Martina Sansavini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.